Geron Q2 Earnings Call Highlights

3 weeks ago 8

MarketBeat

Wed, August 5, 2026 astatine 8:04 AM CDT 6 min read

Key Points

Interested successful Geron Corporation? Here are 5 stocks we similar better.
Geron reported beardown second-quarter performance, with gross rising 17% twelvemonth implicit twelvemonth to $57.5 cardinal and first-half gross up astir 24%. The institution ended the 4th with $327 cardinal successful cash, equivalents, restricted currency and marketable securities.
RYTELO request accrued 5% sequentially, portion prescribing accounts grew 8% to astir 1,575. Geron present expects 2026 RYTELO gross toward the mid-to-high extremity of its existing $220 million–$240 cardinal guidance range.
Geron continues advancing RYTELO's real-world grounds and its Phase III IMpactMF myelofibrosis trial, portion exploring European commercialization options. The institution expects to update investors connected its European strategy earlier the extremity of 2026.

Geron Corporation: FDA Approval Fuels Stock Price Surge

Geron (NASDAQ:GERN) reported second-quarter nett gross of $57.5 million, up 17% from a twelvemonth earlier and 11% sequentially, arsenic the institution continued to grow usage of RYTELO among patients with lower-risk myelodysplastic syndromes, oregon MDS.

Chief Executive Officer Harout Semerjian said first-half nett gross roseate astir 24% from the aforesaid play successful 2025, portion full operating expenses declined 4%. The institution ended the 4th with $327 cardinal successful cash, currency equivalents, restricted currency and marketable securities.

→ SpaceX's First Earnings Report Could Decide Whether Shorts oregon Bulls Have Control

Geron Stock Doubles After Imetelstat Receives FDA Panel Approval

"We delivered different 4th of nett gross growth, expanding RYTELO's scope to much eligible patients," Semerjian said. "We delivered different 4th of nett gross growth, expanding RYTELO's scope to much eligible patients, strengthened the objective grounds supporting RYTELO, continued investing successful aboriginal maturation opportunities, each portion remaining financially disciplined."

RYTELO Demand and Commercial Execution

Geron said RYTELO request accrued 5% successful the 2nd 4th compared with the archetypal quarter, marking its 3rd consecutive 4th of request growth. The fig of prescribing accounts accrued 8% to astir 1,575 since the product's launch.

→ Why Rare Earth Processing Could Be the Real 2027 Opportunity

Ahmed ElNawawi, Geron's main commercialized officer, said diligent starts successful the first- and second-line settings represented 34% connected a rolling 12-month basis. The institution is prioritizing high-volume assemblage attraction centers, earlier recognition of eligible patients, relationship absorption and targeted engagement with health-care professionals.

Read Entire Article